296 related articles for article (PubMed ID: 25059314)
1. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients.
Frederick LR; Cakir OO; Arora H; Helfand BT; McVary KT
J Sex Med; 2014 Oct; 11(10):2546-53. PubMed ID: 25059314
[TBL] [Abstract][Full Text] [Related]
2. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA.
Mulhall JP; Luo X; Zou KH; Stecher V; Galaznik A
Int J Clin Pract; 2016 Dec; 70(12):1012-1018. PubMed ID: 28032424
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
4. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
[TBL] [Abstract][Full Text] [Related]
5. The Association Between Insomnia, Insomnia Medications, and Erectile Dysfunction.
Belladelli F; Li S; Zhang CA; Del Giudice F; Basran S; Muncey W; Glover F; Seranio N; Fallara G; Montorsi F; Salonia A; Eisenberg ML
Eur Urol Focus; 2024 Jan; 10(1):139-145. PubMed ID: 37690918
[TBL] [Abstract][Full Text] [Related]
6. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
7. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
8. Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction.
McVary K; Foley KA; Long SR; Sander S; Curtice TG; Shah H
Curr Med Res Opin; 2008 Mar; 24(3):775-84. PubMed ID: 18237458
[TBL] [Abstract][Full Text] [Related]
9. Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial.
Moncada I; Martínez-Jabaloyas JM; Rodriguez-Vela L; Gutiérrez PR; Giuliano F; Koskimaki J; Farmer IS; Renedo VP; Schnetzler G
J Sex Med; 2009 Dec; 6(12):3469-77. PubMed ID: 19796051
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
[TBL] [Abstract][Full Text] [Related]
11. The EPIFARM study: an observational study in 574 community pharmacies in Spain characterizing patient profiles of men asking for erectile dysfunction medication.
Morales AM; Ibáñez J; Machuca M; Pol-Yanguas E; Schnetzler G; Renedo VP
J Sex Med; 2010 Sep; 7(9):3153-60. PubMed ID: 20584119
[TBL] [Abstract][Full Text] [Related]
12. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
13. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
[TBL] [Abstract][Full Text] [Related]
14. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
15. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
Scranton RE; Goldstein I; Stecher VJ
J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
18. Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.
Travison TG; Hall SA; Fisher WA; Araujo AB; Rosen RC; McKinlay JB; Sand MS
J Sex Med; 2011 Nov; 8(11):3051-7. PubMed ID: 21834873
[TBL] [Abstract][Full Text] [Related]
19. Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness Survey.
Foster SA; Annunziata K; Shortridge EF; Freedman D; Viktrup L
Curr Med Res Opin; 2013 Dec; 29(12):1709-17. PubMed ID: 23971532
[TBL] [Abstract][Full Text] [Related]
20. An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance.
Burnett AL; Rojanasarot S; Amorosi SL
Urology; 2021 Mar; 149():140-145. PubMed ID: 33309705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
